Mandate

Vinge has advised Magle Chemoswed Holding AB in connection with its listing on Nasdaq First North Growth Market

Vinge has provided capital markets and transaction advice in connection with Magle Chemoswed Holding AB’s listing on Nasdaq First North Growth Market.

The prospectus was published on 2 June 2020 and trading on Nasdaq First North Growth Market was commenced on 30 June 2020. The offer related to 25 per cent of the total number of existing shares and following full subscription the value of the offer amounted to SEK 50 million.

Magle Chemoswed is an international contract development and manufacturing company and also develops its own product portfolio based on the company’s technology platforms. The company owns its manufacturing and development facilities in Malmö and works in relation to the development and manufacture of pharmaceuticals and medical devices on a contract basis. On 31 March 2020, the company had 70 employees and in 2019, the net turnover amounted to approximately SEK 128 million.

Vinge’s team consisted primarily of Kristian Ford, Christian Lindhé, Martin Svanberg, Sophia Reutercrona, Niklas Törnell, Tilda Hall, Daniel Melander Björner and Johan Cederblad.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025